Photoprotection

Photoprotection is protection from the damage caused by ultraviolet (UV) and visible light, used here to describe protection of human skin. These wavelengths of light (10-750nm) have a range of damaging effects on skin, including: sunburn, photoaging, carcinogenesis (development of cancer) and a host of symptoms specific to certain medical conditions.

Eumelanin (henceforth referred to simply as melanin) is the brown-black coloured pigment produced by the skin. It acts as a photoprotectant by absorbing part of the incoming UV radiation and dissipating it safely as heat. Its properties of reflectance also make melanin capable of scattering and refracting damaging UV rays away from the skin.

SCENESSE® (afamelanotide) has been developed to provide photoprotection to patients diagnosed with UV and light related disorders of the skin. It does so by enhancing the production of this protective pigment, melanin, in the skin.

Melanin is produced in the outermost later of the skin, the epidermis, in a specific type of cell known as a melanocyte. When SCENESSE® is administered it comes into direct contact with the melanocytes. There it binds to receptors on the outside of the cells called melanocortin 1, or MC1R. This binding activates a series of chemical reactions which lead to an increase in the production of melanin. The process of melanin synthesis is known as melanogenesis.

Melanin is made and stored in a small pouch inside the melanocyte, called a melanosome. The melanosomes are then transported from the melanocyte, via tentacle-like projections called dendrites, to another type of cell on the surface of the skin – keratinocytes. Once inside the keratinocytes, the melanosomes containing the melanin granules spread out like an umbrella and protect the skin cells and their genetic information from damage caused by UV light exposure.

SCENESSE® provides photoprotection by creating this biological barrier of melanin between UV light and the skin.

SCENESSE® Blog Posts

In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...

Read More

Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation...

Read More

Following on from last week’s conversation, I left off with the issues surrounding the off-label prescriptive habits by physicians and...

Read More

SCENESSE® Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now